Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant QL1706 plus lenvatinib for resectable hepatocellular carcinoma
ChiCTR2500098165Phase 4Recruiting
- Sponsor
- Suibei People's Hospital
- Start
- Mar 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iparomlimab + tuvonralimab and lenvatinib in hepatocellular carcinoma (HCC), sponsored by Suibei People's Hospital. Primary endpoints: major pathological response rate and R0 resection rate. Started Mar 2025; status: recruiting.
02
Drugs
iparomlimab + tuvonralimablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500098165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098165.